Arcus Biosciences Inc. (RCUS) and Cytori Therapeutics Inc. (NASDAQ:CYTX) Contrasting side by side

Arcus Biosciences Inc. (NYSE:RCUS) and Cytori Therapeutics Inc. (NASDAQ:CYTX), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation of the two firms.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Arcus Biosciences Inc. 8.35M 62.22 49.59M -1.18 0.00
Cytori Therapeutics Inc. 6.05M 0.61 21.15M -3.90 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Arcus Biosciences Inc. and Cytori Therapeutics Inc.


Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Arcus Biosciences Inc. -593.89% 0% 0%
Cytori Therapeutics Inc. -349.59% -261.3% -79.5%


The current Quick Ratio of Arcus Biosciences Inc. is 16 while its Current Ratio is 16. Meanwhile, Cytori Therapeutics Inc. has a Current Ratio of 0.6 while its Quick Ratio is 0.4. Arcus Biosciences Inc. is better positioned to pay off its short-term and long-term debts than Cytori Therapeutics Inc.

Insider and Institutional Ownership

Arcus Biosciences Inc. and Cytori Therapeutics Inc. has shares owned by institutional investors as follows: 50.2% and 6.8%. 0.9% are Arcus Biosciences Inc.’s share owned by insiders. Comparatively, insiders own roughly 2.42% of Cytori Therapeutics Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Arcus Biosciences Inc. 2.04% 17.99% 4.17% -13.85% 0% 11.42%
Cytori Therapeutics Inc. -8.29% -28.42% -26.18% -57.89% -92.62% -17.24%

For the past year Arcus Biosciences Inc. had bullish trend while Cytori Therapeutics Inc. had bearish trend.


Arcus Biosciences Inc. beats Cytori Therapeutics Inc. on 7 of the 10 factors.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody. The company was founded in 2015 and is headquartered in Hayward, California.

Cytori Therapeutics, Inc. develops cellular therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy, which is in Phase III pivotal clinical trial for the treatment of impaired hand function in scleroderma. It also offers Celution System devices, proprietary enzymes, and sterile consumable sets that are used at the point-of-therapeutic application or at an off-site processing center; and StemSource cell and tissue banking systems, as well as surgical accessories and instruments. The company also provides ATI-0918, a liposomal encapsulation of doxorubicin for use in treating breast cancer, ovarian cancer, multiple myeloma, and KaposiÂ’s Sarcoma; and ATI-1123, a liposomal formulation of docetaxel for the treatment of non-small cell lung cancer, breast cancer, squamous cell carcinoma of the head and neck cancer, gastric adenocarcinoma, and hormone refractory prostate cancer. It serves hospitals, clinics, physicians, researchers, and other customers for commercial and research purposes through direct sales force, third-party distributors, independent sales representatives, and partners worldwide. The company was founded in 1996 and is headquartered in San Diego, California.